Novel homozygous splicing mutations in ARL2BP cause autosomal recessive retinitis pigmentosa by Fiorentino, A et al.
Retinitis pigmentosa (RP; OMIM: 268000) is the most 
common inherited retinal dystrophy, affecting approximately 
1 in 3,000 individuals [1]. RP is characterized by progres-
sive degeneration of the retina, typically starting in the 
midperiphery and advancing toward the macula and fovea. 
Affected individuals commonly present with nyctalopia and 
peripheral visual field constriction, with significant loss of 
central vision as the macular cones become involved at later 
stages of disease progression [2]. RP can occur in isolation 
(non-syndromic RP) or with additional systemic manifesta-
tions (syndromic RP). The genetic etiology of RP is remark-
ably heterogeneous, with autosomal-dominant, autosomal-
recessive, and X-linked modes of inheritance and at least 86 
disease-causing genes identified for the autosomal-recessive 
form alone (The Retinal Information Network; accessed 
February 7, 2018). The genes implicated are involved in 
numerous pathways in the retina, including phototransduc-
tion, retinal metabolism, RNA splicing, and ciliogenesis [3,4].
Variants in genes coding for proteins involved in the cilia 
structure or function account for at least 36% of genetically 
diagnosed cases of RP, and can be classified as ciliopathies 
based on protein localization and function [5]. Mutations in 
ciliopathy genes can cause isolated RP or syndromic disease, 
such as Bardet-Biedl syndrome and Usher syndrome [5-7]. 
Cilia assembly and maintenance require coordinated intrafla-
gellar transport of proteins from the basal body along the 
axoneme to the tip of the cilium, fundamental not only for 
phototransduction but also for photoreceptor survival [8,9]. 
ARL2BP (Gene ID: ENSG00000102931, OMIM: 615407) 
encodes ADP-ribosylation factor-like 2 (ARL2) binding 
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Purpose: Mutations in ARL2BP, encoding ADP-ribosylation factor-like 2 binding protein, have recently been implicated 
as a cause of autosomal recessive retinitis pigmentosa (arRP), with three homozygous variants identified to date. In this 
study, we performed next-generation sequencing to reveal additional arRP cases associated with ARL2BP variants.
Methods: Whole-genome sequencing (WGS) or whole-exome sequencing (WES) was performed in 1,051 unrelated 
individuals recruited for the UK Inherited Retinal Disease Consortium and NIHR-BioResource Rare Diseases research 
studies. Sanger sequencing was used to validate the next-generation sequencing data, and reverse transcriptase (RT)–
PCR analysis was performed on RNA extracted from blood from affected individuals to test for altered splicing of 
ARL2BP. Detailed phenotyping was performed, including clinical evaluation, electroretinography, fundus photography, 
fundus autofluorescence imaging, and spectral-domain optical coherence tomography.
Results: Homozygous variants in ARL2BP (NM_012106.3) were identified in two unrelated individuals with RP. The 
variants, c.207+1G>A and c.390+5G>A, at conserved splice donor sites for intron 3 and intron 5, respectively, were 
predicted to alter the pre-mRNA splicing of ARL2BP. RT–PCR spanning the affected introns revealed that both variants 
caused abnormal splicing of ARL2BP in samples from affected individuals.
Conclusions: This study identified two homozygous variants in ARL2BP as a rare cause of arRP. Further studies are 
required to define the underlying disease mechanism causing retinal degeneration as a result of mutations in ARL2BP 
and any phenotype-genotype correlation associated with residual levels of the wild-type transcript.
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protein (ARL2BP or BART). It is an effector protein of the 
small GTP-binding proteins ARL2 and ARL3, and localizes 
to the distal part of the connecting cilium in photoreceptors 
and to the basal body of ciliated cells [10]. Three variants 
in ARL2BP in three unrelated families have been previously 
reported as causative of RP, with or without situs inversus 
[10,11].
The identification of disease-causing mutations in RP has 
been accelerated by the implementation of next-generation 
sequencing (NGS) technologies. For affected individuals who 
lack a molecular diagnosis, whole-exome sequencing (WES) 
and whole-genome sequencing (WGS) are effective tools for 
identifying new potential causative variants [12].
In our collaborative study of unsolved cases, through 
the UK Inherited Retinal Disease Consortium and NIHR-
BioResource Rare Diseases research study, 1,051 unrelated 
individuals were analyzed with WES or WGS. In this report, 
we describe two unrelated families, with no known consan-
guinity, in whom WES or WGS revealed homozygous vari-
ants affecting the mRNA processing of ARL2BP.
METHODS
Clinical assessment of study families: The study protocols 
adhered to the tenets of the Declaration of Helsinki and 
received approval from the local Ethics Committee of the 
participating institutions: Moorfields Eye Hospital and 
Oxford Eye Hospital. Written, informed consent was obtained 
from all participants before they were included in this study. 
The two probands underwent detailed clinical examination, 
including best-corrected decimal visual acuity (BCVA), 
35-degree color fundus photography (TRC-NW8; Topcon 
(Great Britain) Medical Ltd., Newbury, UK), ultrawidefield 
confocal scanning laser imaging (Optos plc, Dunfermline, 
UK), fundus autofluorescence (FAF) imaging (Spectralis, 
Heidelberg Engineering Inc., Carlsbad, CA), and spectral-
domain optical coherence tomography (SD-OCT; Spectralis, 
Heidelberg Engineering Inc.).
Next-generation sequencing: DNA samples for the two 
probands were analyzed with WES in family 1 [13] and WGS 
in family 2 [12] as follows. For the WES analysis, genomic 
DNA was processed according to the Agilent SureSelect XT 
Library Prep protocol (Agilent Technologies, Santa Clara, 
CA) with capture using a SureSelect Exome V5 Capture 
library. After hybridization and indexing, 100 bp paired end 
sequencing was performed (Illumina HiSeq 2500 sequencer, 
Illumina Inc., San Diego, CA). Reads were aligned to the 
hg19 human reference sequence (build GRCh37) using 
Novoalign v.2.08 (Novocraft, Selangor, Malaysia). Duplicate 
reads were marked with Picard tools MarkDuplicates. 
Variant calling was performed using GATK, creating gVCF 
formatted files for each sample. The final variant calling 
for individual gVCF files was performed using the GATK 
Genotype gVCFs module. The variant quality scores were 
then recalibrated separately for indels and single nucleotide 
variants (SNVs). Resulting variants were annotated using 
ANNOVAR based on Ensembl gene and transcript defini-
tions. Candidate variants were filtered based on function 
(non-synonymous, presumed loss-of-function, or splicing) 
and a minor allele frequency (MAF) of <0.005 using several 
data sets, including an in-house exome-sequencing control 
data set of approximately 4,000 individuals (UCLEx), NHLBI 
GO Exome Sequencing Project (EVS), and 1000 Genomes 
phase 1 data set. Variants were further manually interrogated 
for variant call quality, predicted pathogenicity, and biologic 
plausibility. Candidate variants were then ranked, considering 
the likely mode of inheritance for each family, prioritizing 
variants with a MAF of <0.001 in the Exome Aggregation 
Consortium (ExAC) database [14] (accessed on 11/01/2017).
WGS was performed using an Illumina TruSeq DNA 
PCR-Free Sample preparation kit (Illumina, Inc.) and an 
Illumina HiSeq 2500, generating minimum coverage of 15X 
for approximately 95% of the genome. Reads were aligned to 
GRCh37 using Isaac Genome Alignment Software (version 
01.14; Illumina, Inc.) [15]. SNVs and small insertion/deletions 
were identified using Isaac Variant Caller (version 2.0.17). To 
identify potentially pathogenic variants, a two-step variant 
filtering protocol was designed, using automated filtering 
followed by a manual review. For SNVs and indels, automated 
filtering identified variants that fulfill the following criteria: 
passes standard Illumina quality filters in >80% of the 
whole NIHR BioResource Rare Diseases cohort (n=6,688); 
predicted to be a high impact, medium impact, or splice 
region variant, or present in the HGMD Pro database; and 
had a MAF <0.01 in the control data sets, including the NIHR 
BioResource Rare Diseases cohort and the Exome Aggre-
gation Consortium (ExAC) database [14]. If a variant was 
present in the HGMD Pro database, a higher MAF threshold 
of 0.1 was used. A manual review of all the variants that 
passed the automated filtering was then performed.
For WES and WGS, candidate variants were then 
prioritized based on previous association of the gene with a 
compatible phenotype and biologic plausibility. Phenopolis 
[16], a platform for studying the pleiotropy of genes, was also 
used to prioritize variants. Copy number variations (CNVs) in 
the genomic region spanning the ARL2BP gene were assessed 
in the WES data using the Exome Depth calling algorithm 
[17] and WGS data using Isaac Copy Number Variant Caller 
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(Canvas, Illumina) and Isaac Structural Variant Caller 
(Manta, Illumina) [12].
Sanger sequencing: PCR amplification and bidirectional 
Sanger sequencing were performed using Go taq Green 
Master Mix (Promega, Madison, WI) with primers flanking 
the variants (Family 1 c.390+5G>A: forward primer CAT 
CTG TTC CG TTT GCA GGC, reverse primer GCC AGT 
TTG AAG GGA GAA TGA TG; Family 2 c.207+1G>A: 
forward primer CCA CAT CAG GGT CCC ATT TA, reverse 
primer CCA CCT CAA CCT CCC AAA TA). 50 ng of DNA 
and a final concentration of 0.4 µM of each mutation-specific 
forward and reverse primer were used for amplification in a 
final volume of 12.5 µl. Amplification was performed for 35 
cycles, each cycle consisted of 30 s at 95 °C, 30 s at 62 °C, 
and 30 s at 72 °C.
Figure 1. Homozygous ARL2BP mutations in families with autosomal recessive retinitis pigmentosa. A: Pedigrees of two study families. 
The arrow indicates the affected proband in each family. The mutation in ARL2BP (NM_012106.3) identified in each family is indicated. 
Mut=ARL2BP mutation present. B: Multiple DNA sequence alignment of orthologs shows that the donor splice site sequences and site of 
mutations (c.207+1 and c.390+5) are highly conserved across different species. C: Schematic of the genomic structure of ARL2BP. Positions 
of mutations in ARL2BP identified in this study (below the gene structure) and previously identified mutations (above the gene structure) 
are indicated (not to scale).
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In silico analysis of ARL2BP variants: The UCSC genome 
browser and Phenopolis [16] were used for visualization 
of existing gene variants and evolutionary conservation. 
Variants in ARL2BP were scored for likelihood of altering 
splicing using several tools: Berkeley Drosophila Genome 
Project Splice Site Prediction [18], NetGene2 [19], and Human 
Splice Finder.
Reverse transcriptase–PCR analysis of ARL2BP: Total 
RNA was extracted from whole blood using blood PAXgene 
Blood RNA collection tubes and a PAXgene Blood purifica-
tion RNA Kit (PreAnalytix, Qiagen/BD, Hombrechtikon, 
Switzerland). cDNA was reverse-transcribed using a cDNA 
synthesis kit with an Oligo (dT) Primer mix (Tetro cDNA 
Syntesis kit, Bioline, Toronto, Canada). The cDNA was then 
amplified from exon 1 (forward primer 5′-CTT TCT CCT 
CCG CCT CTG AT-3′) to exon 6 (reverse primer 5′-TCA 
Figure 2. Retinal imaging of the probands of family 1 and family 2. Family 1. A, B: Optos widefield color fundus imaging showing intraretinal 
bone spicule-like pigmentation mainly in the nasal retina, generalized vascular attenuation, and optic nerve pallor. C, D: Autofluorescence 
imaging (Heidelberg Spectralis) showing inferiorly a reduced signal intensity in the outer macula and the midperiphery compatible with the 
loss of the outer retinal structure in these areas. Conversely, the foveal region appears intact bilaterally. E, F: Spectralis optical coherence 
tomography (OCT) images of the proband showing normal macular architecture. Family 2. G, H: Optos widefield color fundus imaging 
showing bilateral macular atrophy, and outer retinal atrophy along the vascular arcades, with scanty bone spicule-like pigmentation mainly 
in the nasal retina. I, L: Optos widefield autofluorescence showing reduced signal at the posterior pole, around the arcades, and nasally, 
with residual autofluorescence at the fovea in both eyes. M, N: Heidelberg Spectralis infrared and OCT images of the proband, age mid-40s, 
showing widespread loss of the photoreceptor layers in both eyes, with a degree of preservation of the outer retinal structure at the fovea 
bilaterally. All images are consistent with widespread loss of the outer retinal structure throughout the fundus bilaterally.
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Figure 3. Aberrant pre-mRNA splicing of ARL2BP as a consequence of homozygous donor splice site mutations. A: Agarose gel electropho-
resis showing the reverse transcriptase (RT)–PCR products (exon 1 to exon 6) from whole blood RNA for affected individuals from family 
1 (1-II:4), family 2 (2-III:2), and a control individual (wild type, WT), as indicated. Multiple ARL2BP transcripts were amplified (forward 
primer 5′-CTT TCT CCT CCG CCT CTG AT-3′, reverse primer 5′-TCA TGA GCT GAG CCT ATT GG-3′) for individual 1-II:4, who is 
homozygous for the c.390+5G>A exon 5 donor site variant. RT–PCR products range in size from 429 bp to 1,035 bp due to aberrant splicing 
of ARL2BP. Corresponding electropherograms are shown for each transcript. A low level (7.1%) of the WT transcript was also detected. 
An abnormal 419 bp transcript was amplified using the same primers in individual 2-III:2, who is homozygous for the c.207+1G>A exon 3 
donor splice site variant. The product was due to exon 3 skipping, shown in the corresponding electropherogram. B: Schematic representa-
tion of the aberrant splicing events identified in individuals homozygous for the c.390+5G>A and c.207+1G>A variants in ARL2BP. Each 
splicing variant is color coded according to the arrows shown in panel A, corresponding to the transcripts detected with RT–PCR. Exons 
are represented by rectangles and introns by lines. * represents the location of the variant.
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TGA GCT GAG CCT ATT GG-3′) to amplify the ARL2BP 
transcripts. 1 µl of cDNA and a final concentration of 0.4 µM 
of each primer were used for amplification in a final volume 
of 25 µl using Go taq Green Master Mix (Promega). Ampli-
fication was performed for 35 cycles, each cycle consisted of 
30 s at 95 °C, 30 s at 62 °C, and 30 s at 72 °C. The resulting 
products were then gel purified (QIAquick Gel Extraction 
Kit, Qiagen, Hilden, Germany) and Sanger sequenced to 
determine the transcripts produced by alternative splicing. 
Quantification of different transcripts was calculated using 
Image Lab Software 6.0.1 (Bio-Rad, Hercules, CA).
RESULTS
ARL2BP variants identified in individuals with retinitis 
pigmentosa: Using a combination of WES and WGS, vari-
ants in ARL2BP were identified in two unrelated individuals 
with RP. The pedigrees of the study families are shown in 
Figure 1A.
A simplex white female (1-II:4) from a non-consan-
guineous family (family 1) was diagnosed with RP aged 35 
years. No other syndromic features were identified. WES 
was performed, and variants were filtered and prioritized as 
described, considering potential recessive inheritance. This 
identified a homozygous ARL2BP variant, c.390+5G>A, as the 
most compelling candidate (GRCh37 Chr16:57284424G>A, 
NM_012106.3: c.390+5G>A). This variant was absent in 
the gnomAD database [14] and was predicted by NetGene2, 
NNsplice, and Human Splice Finder to disrupt the donor 
splice site of exon 5. No CNVs were detected in ARL2BP. 
Sanger sequencing confirmed the variant in the affected 
female proband.
The proband (GC21134, 2-III:2) of family 2, from a 
North African non-consanguineous family (self-reported), 
was diagnosed with RP at age 36 years. WGS was performed 
as part of the NIHR-BioResource Rare Diseases research 
study [12], and variants were filtered and prioritized as 
described considering potential recessive inheritance. A 
homozygous variant, c.207+1G>A, in ARL2BP (GRCh37 
Chr16:57282556G>A, NM_012106.3: c.207+1G>A) was iden-
tified as the most probable cause of disease. The variant alters 
the invariant GT dinucleotide at the splice donor site of exon 
3. This variant has an MAF of 0.0001071 in the gnomAD 
database [14], consistent with an allele frequency for a reces-
sive condition, with no homozygous individuals present in the 
database. The variant was predicted by NetGene2, NNsplice, 
and Human Splice Finder to disrupt the donor splice site 
of exon 3. Sanger sequencing confirmed the variant in the 
affected male proband. No CNVs were detected in ARL2BP. 
Both variants are located at highly conserved splice donor 
sites in ARL2BP (Figure 1B).
Phenotypic comparison of affected individuals: A white 
female (1-II:4) presented at 35 years of age with slow dark 
adaptation and mild photosensitivity. There was no family 
history of inherited eye disease, and general health was excel-
lent, with no syndromic features. After 7 years of follow-up, 
at age 42 years, she had normal visual acuity of OD 0.04 
LogMAR (6/6 Snellen equivalent) and OS 0.02 (6/6). Gold-
mann visual field testing at presentation showed generalized 
constriction to all test targets; although she was able to 
continue driving until 40 years of age, by which time there 
was moderate infero- and superotemporal constriction in the 
left eye and inferotemporal loss in the right eye. Fundoscopy 
and retinal imaging showed intraretinal bone spicule-like 
pigmentation mainly in the nasal retina, generalized vascular 
attenuation, and optic nerve pallor (Figure 2A,B). SD-OCT 
showed normal macular architecture (Figure 2E,F), but FAF 
imaging revealed symmetric bilateral perimacular rings of 
increased signal, also extending bilaterally inferiorly and in 
the right eye also superiorly, with patchy reduced AF in the 
midperiphery (Figure 2C,D). Electrophysiological assess-
ment showed greater generalized rod than cone loss, with 
significant reduction in rod amplitudes (Appendix 1). Other 
investigations included normal karyotyping and normal 
phytanic acid levels. There were no signs of situs inversus 
(self-reported).
A male (2-III:2, GC21134) from a North African non-
consanguineous family presented at 36 years of age with night 
blindness when he was diagnosed with retinitis pigmentosa. 
There was no family history and no evidence of systemic 
illness (situs inversus not investigated). Since diagnosis, there 
has been slow progressive loss of peripheral vision and more 
recently, of central vision. His BCVAs at age 41 years were 
20/60 right and 20/40 left. By 48 years of age, his acuities 
had decreased to 20/110 (LogMar 0.74) right and 20/83 left 
(LogMar 0.62). From the age of 41 years, all peripheral visual 
field outside the central 10 degrees had been lost bilaterally. 
Images in Figure 2C–H show the extensive degeneration at 
age 45 years (right more than left).
Fundus examination showed bilateral macular and 
peripheral retinal atrophy with widespread intraretinal bone 
spicule-like pigmentation (Figure 2G, H). Fundus autofluo-
rescence (Optos) showed signal reduction at the posterior 
pole, around the temporal vascular arcades, and throughout 
the nasal retina (Figure 2I, L). On OCT, there was widespread 
loss of the outer retinal structure with some preservation of 
the foveal photoreceptor layer (Figure 2M, N), corresponding 
to residual autofluorescence at the fovea (Figure 2I, L).
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ARL2BP variants alter pre-mRNA splicing: RT–PCR analysis 
was performed on cDNA derived from RNA extracted from 
blood samples for the two affected individuals and controls, 
and the resulting transcripts were Sanger sequenced. ARL2BP 
transcripts in affected individuals were aberrantly spliced 
(Figure 3).
In individual 1-II:4, the homozygous c.390+5G>A muta-
tion within the donor splice site for exon 5 resulted in five 
different transcripts: Four transcripts revealed abnormal 
splicing events, including exon 5 skipping and intron 5 
inclusion, predicted to result in premature termination of 
the protein (Figure 3A). Exon 5 was skipped in the most 
abundant transcript (representing 75.2% of the total tran-
script), resulting in a frameshift and premature termination 
p.(His99Lysfs*9; NM_012106.3). In three other aberrant tran-
scripts, alternative acceptor and donor sites were activated, 
resulting in the inclusion of part of intron 5 (Figure 3A, B). 
The predicted consequence of these events is an insertion 
of 55 bp, 189 bp, and 509 bp resulting in p.(Glu131Glyfs*9), 
p.(Glu131_His163delinsGlyLysLeuLeuLeuLeuPheIle), and 
p.(Glu131Glyfs*9), respectively. These three aberrant tran-
scripts represent 7.2%, 9.1%, and 1.4% of the total transcript, 
respectively. A normally spliced ARL2BP transcript was also 
detected (Figure 3A) representing only 7.1% of the total tran-
script. In individual 2-III:2, only one transcript was detected 
that represents exon 3 skipping, predicted to lead to a frame-
shift and premature termination codon p.(Asp35Phefs*8; 
Figure 3A, B).
DISCUSSION
Davidson and colleagues [10] first described biallelic muta-
tions in ARL2BP associated with arRP in two families. An 
additional family was subsequently identified by Audo et al. 
[11]. These studies described homozygous ARL2BP missense 
and splice site variants (c.101–1G>C, c.134T>G [p.Met45Arg], 
c.207+1G>T) in arRP cases of Arab-Muslim, European, and 
Moroccan origin (Figure 1C). In this study, we identified two 
novel homozygous variants in ARL2BP in two unrelated RP 
cases that result in aberrant pre-mRNA splicing. Interest-
ingly, the only missense variant identified is in exon 3 [10] 
(Figure 1C), suggesting a critical function of this exon in 
photoreceptor homeostasis.
One variant, c.207+1G>A, identified in this study occurs 
at the same location as a previously described mutation 
c.207+1G>T [11], and both variants cause exon 3 skipping 
(Figure 3). The other two splice site variants identified, 
c.101–1G>C [10] and c.390+5G>A, predominantly cause 
abnormal splicing, but evidence of low levels of wild-type 
ARL2BP transcript was detected in both cases (Figure 3) [10].
A comparison of the phenotypes described for all cases 
attributed to mutations in ARL2BP is presented in Table 1. 
In this study, the two probands presented at similar ages, 
although patient 2-III:2 (GC21134), in whom no normal tran-
script was detected, appeared to suffer more severe loss of 
the central retinal structure compared to patient 1-II:4. This 
may indicate the consequences of a decreased rather than a 
complete absence of ARL2BP protein, with residual levels of 
wild-type transcript and protein resulting in a milder pheno-
type. However, in the absence of animal models, further cases 
need to be described before any phenotype-genotype correla-
tions can be made for this rare condition.
APPENDIX 1. INTERNATIONAL-STANDARD FULL-
FIELD ERGS AND PATTERN ERG (PERG) FOR II:4, 
FAMILY 1.
To access the data, click or select the words “Appendix 1.”
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